TYR and melanoma: Finally, the cytotoxicity of two tyrosinase inhibitors and two tyrosinase activators was assessed in melanoma cell lines (B16F1/B16F10), as well as their ability to moderate tyrosinase activity and affect melanin production (Table 1).